NEW YORK (GenomeWeb News) – Saladax Biomedical today announced exclusive distribution deals for its My5-FU diagnostic test in Poland and Italy.
Saladax has appointed Genoxa of Puck, Poland to be its distributor of the test to oncologists in Poland, and AB Analitica of Padua, Italy to distribute the test to hospitals and reference laboratories in Italy.
My5-FU measures levels of the anti-cancer drug 5-fluorouracil in the blood of cancer patients, allowing oncologists to determine proper dosing for individual patients.
"Our new partnership with AB Analitica and Genoxa continues the expansion of our marketing and distribution channels in Europe, which will facilitate adoption of 5-FU dose management in these new markets for Saladax," said Adrienne Choma, senior vice president and chief marketing officer of Saladax, in a statement.
Financial and other terms of the deals, which follow a distribution agreement for the My5-FU test in Turkey in August, were not disclosed.